Cargando…
Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer
Oncogenic KRAS-mutant lung cancers remain treatment refractory. A better understanding of the immune response of KRAS-mutant lung cancers is required to facilitate the development of potential therapeutic strategies. Regulatory T cells (Tregs) are a subset of immune cells that promote tumor progress...
Autores principales: | Kim, Byung-Seok, Clinton, Jelita, Wang, Qing, Chang, Seon Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959450/ https://www.ncbi.nlm.nih.gov/pubmed/32002289 http://dx.doi.org/10.1080/2162402X.2019.1682380 |
Ejemplares similares
-
Interleukin-17D Promotes Pathogenicity During Infection by Suppressing CD8 T Cell Activity
por: Lee, Younghee, et al.
Publicado: (2019) -
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016) -
Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021) -
Targeting KRAS mutant lung cancer: light at the end of the tunnel
por: Drosten, Matthias, et al.
Publicado: (2022) -
Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)